Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight notable findings from the ATTR-ACT trial, with users referencing data such as '30-mo mortality 29.5% vs 42.9% on placebo' and the significance of a 30% reduction in all-cause mortality. The tone is generally positive, with phrases like 'game changer' used to describe the potential of tafamidis. Users also mention its FDA approval, indicating a strong belief in its clinical value, which contributes to the overall enthusiasm and perceived importance of the treatment.
The majority of discussions reflect a general consensus on the effectiveness of tafamidis, with several users expressing strong support for the findings.
There is a noticeable excitement around the publication, with many users expressing curiosity and sharing additional insights and studies.
Participants are deeply engaged with the topic, referencing specific trials, data, and real-world implications of tafamidis in clinical practice.
Many users believe tafamidis has significant potential impact on treatment protocols for patients with transthyretin amyloid cardiomyopathy.
Just had an amazing lecture by @MathewMaurer on the ATTR-ACT study in NEJM - underused treatment for an underdiagnosed illness https://t.co/ls6yih8n1r https://t.co/G7aGRLbPvN
@KevinShahMD @GiuseppeGalati_ @NatureMedicine @US_FDA @EMA_News @DLBHATTMD @DrMarthaGulati @DBelardoMD @gbiondizoccai @SABOURETCardio @ShelleyZieroth @DrRajivsankar @rahatheart1 @mmamas1973 @iamritu @AnastasiaSMihai @ValleAlfonso @DocSavageTJU @KardiologieHH Tafamidis (ATTR-ACT) was approved on the basis of win ratio. https://t.co/hDwnh57i44 ATTRibute-CM study of acoramidis (BridgeBio) has a co-PEP of hierarchical combination of all-cause mortality, CV hosp, & 6MWD at 30months. Device trials are increasingly utilizing this endpoint.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy help me with you coment and like (ayudame con un comentario y un like) https://t.co/xEavlVO2g6
@shimjes @David_Ouyang @rodney_falk It did just fine. Key seems to have been a much higher % of variant patients than WT patients. https://t.co/pTvvstpki7
Speaking as a long-time member of team tafamidis, I really hope the $BBIO acoramidis trial continues to a meaningful endpoint. For whatever reason, the whole cohort is doing a lot better than the ATTR-ACT cohort. (Which is great news for the participants!) https://t.co/8EeX3rbuVD https://t.co/nCqrMy1Dke
Hopefully this helps others navigate the complexities of these processes. The ATTR-ACT trial showed mortality benefit and reduction in HF hospitalizations. And in our experience patients stabilize on tafamidis and at times improve (anecdotes, noted). https://t.co/yp2wm19cLS https://t.co/RKrq0WaSyV
This video reviews the top 10 cardiology trials of 2018, highlighting significant studies including those on PCI strategies in cardiogenic shock and the effects of various treatments on cardiovascular outcomes. Discover…
This week, John Mandrola MD discusses translation science leading to beneficial drugs for heart diseases, with a focus on tafamidis treatment for transthyretin amyloid cardiomyopathy. Tafamidis stabilizes abnormal…
@CdricLabrousse Ainsi pour ne prendre l’exemple que des médicaments, certains blockbusters se justifient d’autres beaucoup moins! https://t.co/CpUlBThxoy Pour ne citer que le 2ieme en montant, le TAFAMADIS dans l’Insuffisance cardiaque en se basant sur l’etude de référence ATTR-ACT,
(7/10) Tafamidis (ATTR-ACT) improved outcomes in ATTR-CM: 30-mo mortality 29.5% vs 42.9% on placebo, and fewer CV hospitalizations. https://t.co/hJteNQn5d7 Vutrisiran’s ~36% mortality risk reduction is comparable, achieved via TTR gene silencing vs TTR stabilization. https://t.co/OjKrsUsYa6
@echo_batman This is the tafamidis trial published in 2018 https://t.co/feBHjGW7Fd
Win ratio analysis has even been used in registrational trials for FDA approval https://t.co/P1EcFASIeF
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/1gzYFLkEzM
RT @cardiomet_CE: 19) The landmark #ATTR-ACT trial tested the stabilizer #tafamidis vs. placebo in pts w/#ATTR-CM ➡️large benefits, includi…
19) The landmark #ATTR-ACT trial tested the stabilizer #tafamidis vs. placebo in pts w/#ATTR-CM ➡️large benefits, including #survival (NNT 7.5 to prevent 1 death at 30 mos!) & CV #hospitalizations (NNT 4.5 to prevent 1 hospitalization each yr!).
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/zUgyXOJBxo
@HeartOTXHeartMD @JAMAInternalMed Favorable CV effects (https://t.co/tOGPPJbBTi @NEJM) but not so favorable in cost-effectiveness analyses (https://t.co/EzwKuaxjsa @CircAHA)
@eliaseythorsson So, here's a medical intervention (TAFAMADIS for transthyretin amyloid cardiomyopathy) with a 30% reduction in all-cause mortality. https://t.co/X4rYEGDR2u
Our ambulatory clinic wrap up session learning point today: In patients with ATTR Cardiomyopathy use of Tafamidis results in ⬇️ Mortality, Hospitalisations, Decline in functional capacity, and ⬆️ Quality of life. https://t.co/mQD92P0vEd
Though mortality in amyloidosis can be improved with the use of a new drug called Tafamidis, which was demonstrated in this 2018 NEJM RCT https://t.co/0ncCkKbyEV 5/X
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy https://t.co/mNJDaBxS33
RT @kaulcsmc: @KevinShahMD @GiuseppeGalati_ @NatureMedicine @US_FDA @EMA_News @DLBHATTMD @DrMarthaGulati @DBelardoMD @gbiondizoccai @SABOUR…
RT @kaulcsmc: @KevinShahMD @GiuseppeGalati_ @NatureMedicine @US_FDA @EMA_News @DLBHATTMD @DrMarthaGulati @DBelardoMD @gbiondizoccai @SABOUR…
@KevinShahMD @GiuseppeGalati_ @NatureMedicine @US_FDA @EMA_News @DLBHATTMD @DrMarthaGulati @DBelardoMD @gbiondizoccai @SABOURETCardio @ShelleyZieroth @DrRajivsankar @rahatheart1 @mmamas1973 @iamritu @AnastasiaSMihai @ValleAlfonso @DocSavageTJU @KardiologieHH Tafamidis (ATTR-ACT) was approved on the basis of win ratio. https://t.co/hDwnh57i44 ATTRibute-CM study of acoramidis (BridgeBio) has a co-PEP of hierarchical combination of all-cause mortality, CV hosp, & 6MWD at 30months. Device trials are increasingly utilizing this endpoint.
@LisaLemond In terms of interestingly done clinical trials, ATTR-ACT for tafamidis (https://t.co/DxGMqXi6hp) and EMPULSE (https://t.co/rGZ3nr6eDk) for empagliflozin were novel designs that changed or will change management. https://t.co/rLBN6IMcxk they may at least worth be considering.
@pranavgarimella @ADAlthousePhD The best example I can recall is tafadmadis in cardiac amyloid. https://t.co/mbThi1e353
RT @wittyremarkhere: Speaking as a long-time member of team tafamidis, I really hope the $BBIO acoramidis trial continues to a meaningful e…
@shimjes @David_Ouyang @rodney_falk It did just fine. Key seems to have been a much higher % of variant patients than WT patients. https://t.co/pTvvstpki7
@DewDiligence Trial design FTW. https://t.co/pTvvstpki7 1:3 m:WT. Acoramidis 1:9 m:WT. See @MSollender thread on subpop results.
@cardiolewis @sciencescanner Worked just fine for tafamidis 1:3 m:WT and in m subpop in acoramidis trial. https://t.co/JX3JZTryTa and https://t.co/pTvvstpki7
@MSollender Tafamidis trial demographics 1:3 m:at instead of 1:9... https://t.co/pTvvstpki7 https://t.co/PdhC2rqJSF
Speaking as a long-time member of team tafamidis, I really hope the $BBIO acoramidis trial continues to a meaningful endpoint. For whatever reason, the whole cohort is doing a lot better than the ATTR-ACT cohort. (Which is great news for the participants!) https://t.co/8EeX3rbuVD https://t.co/nCqrMy1Dke
Fact #4: Diagnostic & treatment delays are major issues - Average of 4 years before diagnosis! Hawkins et al. Transthyretin Cardiac #Amyloidosis - Tafamidis showed reductions in mortality and cardiovascular-related hospitalizations. #WorldAmyloidosisDay https://t.co/R0AVZ9S23T
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/B3VSBCEJYP
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy help me with you coment and like (ayudame con un comentario y un like) https://t.co/xEavlVO2g6
Trial: ATTR-ACT In patients with transthyretin (prealbumin) cardiac amyloidosis , tafamifis (Vyndaqel) decreased all cause mortality and cardiovascular related hospitalisation when compared to placebo. Source: https://t.co/zoZ7kRq0Sy
https://t.co/BerUDCkRZE
@mmc_im in this double-blinded clinical trial, tafamidis (TTR stabilizer, first fda approved drug for transthyretin cardio amyloidosis) showed lower all-cause mortality vs placebo https://t.co/4wWXJwGvsM
@jpcostabel The new england journal of medicine established in 1812 September 13, 2018 vol. 379 no. 11 Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Mathew S. Maurer, M.D., Jeffrey H. Schwartz, Ph.D., Balarama Gundapaneni.. Ojalá podamos acceder un día ojala..
5. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy https://t.co/i99I2PxI7j. Currently not NICE recommended https://t.co/TBjdTi6wO7.
Just had an amazing lecture by @MathewMaurer on the ATTR-ACT study in NEJM - underused treatment for an underdiagnosed illness https://t.co/ls6yih8n1r https://t.co/G7aGRLbPvN
I am recently thinking about cardiac amyloidosis a bit - largely because of trials like this https://t.co/rF60c1WiR1 I now find myself struggling to understand how this heart failure trial was published without detailing heart failure meds at the end (given for start) , & 1/3
@Eric_Fauman Agree that no common variant evidence (yet) but through the ATTR-ACT trial strong evidence of benefit + FDA/EMA approval for TTR stabilization also in common wild-type transthyretin amyloidosis https://t.co/Ne1mjoyFi4
This week, our resident (@pharmgabbs) is leading a topic discussion on a specialty medication that is new to SPS.
What about treatment? There is a good RCT from NEJM 2018 about all cause mortality benefit for Tafamidis for TTR amyloid, https://t.co/TA784mxduK Teaching points overview by @sukritibanthiya https://t.co/9o7OOiUOdY
Hopefully this helps others navigate the complexities of these processes. The ATTR-ACT trial showed mortality benefit and reduction in HF hospitalizations. And in our experience patients stabilize on tafamidis and at times improve (anecdotes, noted). https://t.co/yp2wm19cLS https://t.co/RKrq0WaSyV
The patient's final diagnosis was wild type ATTR amyloidosis. Tafamidis is now FDA approved for both wild type and hereditary ATTR amyloidosis, NYHA class I-III to reduce CV death and hospitalization based on the ATTR-ACT study https://t.co/8SDE2L3HBa https://t.co/ft01xvwk68
@jinkei0626 あざす！昨年のこの論文とタファミジスの保険適応で、今年ある意味トピックスです。https://t.co/JVrV8cuN6E
Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis https://t.co/fhxe5W9LIG , ATTR-ACT trial https://t.co/uuEDqnBTE7
TAFAMIDIS TREATMENT FOR PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. https://t.co/3VlrX6xonJ via
@avidresearch https://t.co/WnY8rJuzNE $PFE #ATTR
@anish_koka @venkmurthy @djc795 @BijoyTelivala @ADAlthousePhD @f2harrell @boback @coachabebe Care to comment re above from the attr act trial dose analysis ? https://t.co/yp2wm0RBUk https://t.co/N3KnT8Cr4K
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy @mjack2050 https://t.co/h1LgXT5Qkw
RT @alliedmeet: Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. To know more: https://t.co/HDw4DrJH0e #cardia…
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. To know more: https://t.co/HDw4DrJH0e #cardiacconference #cardiacsurgerymeet #cardiologygathering #healthylife #cardiacrhymth #cardiolife #cardiology #cardiologists #alliedacademies #conferences #cardio https://t.co/vRYk3v7nJR
FDA approval of tafamidis for TTR amyloidosis is a big deal since ATTR-ACT study showed it improved mortality, CV hospitalizations, functional class and quality of life in patients with TTR amyloidosis, which underdiagnosed. @tonkhueMdPhd https://t.co/rWWEsWCB2k #cardiotwitter https://t.co/Cuj1cL2EkF
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/f27PVBwDwj
RT @AndreasGevaert: 1/3 #ESCcongress #heartfailure wrapup @escardio 1. ATTR-ACT: Tafamidis ⬇️ mortality/CVhosp/symptoms in cardiac #amyloi…